Rolf Wachter
A5090498630- Heart Failure Treatment and Management
- Atrial Fibrillation Management and Outcomes
- Cardiovascular Function and Risk Factors
- Cardiac Arrhythmias and Treatments
- Acute Ischemic Stroke Management
- Cardiac pacing and defibrillation studies
- Cardiac Health and Mental Health
- Cardiovascular and exercise physiology
- Heart Rate Variability and Autonomic Control
- Blood Pressure and Hypertension Studies
- Cardiac Imaging and Diagnostics
- Cardiovascular Syncope and Autonomic Disorders
- Cardiac electrophysiology and arrhythmias
- Venous Thromboembolism Diagnosis and Management
- Cerebrovascular and Carotid Artery Diseases
- Potassium and Related Disorders
- Cardiac Valve Diseases and Treatments
- Cardiovascular and Diving-Related Complications
- Chronic Disease Management Strategies
- Cardiac Structural Anomalies and Repair
- Health Systems, Economic Evaluations, Quality of Life
- Diabetes Treatment and Management
- Pulmonary Hypertension Research and Treatments
- Acute Myocardial Infarction Research
- Diet and metabolism studies
Universitätsmedizin Göttingen
2016-2025
German Centre for Cardiovascular Research
2016-2025
University Hospital Leipzig
2017-2025
Klinik und Poliklinik für Neurologie
2017-2025
Leipzig Heart Institute
2025
University of Göttingen
2015-2024
Leipzig University
2013-2024
Johannes Gutenberg University Mainz
2011-2023
University Medical Center of the Johannes Gutenberg University Mainz
2018-2023
National and Kapodistrian University of Athens
2022
Diastolic heart failure (ie, with preserved ejection fraction) is a common condition without established therapy, and aldosterone stimulation may contribute to its progression.To assess the efficacy safety of long-term receptor blockade in fraction. The primary objective was determine whether spironolactone superior placebo improving diastolic function maximal exercise capacity patients fraction.The Aldo-DHF trial, multicenter, prospective, randomized, double-blind, placebo-controlled trial...
To assess tolerability and optimal time point for initiation of sacubitril/valsartan in patients stabilised after acute heart failure (AHF).TRANSITION was a randomised, multicentre, open-label study comparing two treatment modalities sacubitril/valsartan. Patients aged ≥ 18 years, hospitalised AHF were stratified according to pre-admission use renin-angiotensin-aldosterone system inhibitors randomised (n = 1002) stabilisation initiate either 12-h pre-discharge or between Days 1-14...
The objective of this clinical trial was to assess the safety and efficacy carotid BAT in advanced HF.Increased sympathetic decreased parasympathetic activity contribute heart failure (HF) symptoms disease progression. Baroreflex activation therapy (BAT) results centrally mediated reduction outflow increased activity.Patients with New York Heart Association (NYHA) functional class III HF ejection fractions ≤35% on chronic stable guideline-directed medical (GDMT) were enrolled at 45 centers...
<h3>Importance</h3> Depression is frequent in patients with heart failure and associated adverse clinical outcomes. Long-term efficacy safety of selective serotonin reuptake inhibitors these are unknown. <h3>Objective</h3> To determine whether 24 months treatment escitalopram improves mortality, morbidity, mood chronic systolic depression. <h3>Design, Setting, Participants</h3> The Effects Selective Serotonin Re-Uptake Inhibition on Morbidity, Mortality, Mood Depressed Heart Failure Patients...
In approximately 20% of atrial fibrillation (AF)-related ischemic strokes, stroke is the first clinical manifestation AF. Strategies are needed to identify and therapeutically address previously undetected AF.To quantify incidence AF in patients at high risk for but without known using an insertable cardiac monitor.This prospective, single-arm, multicenter study was conducted from November 2012 January 2017. Visits took place 57 centers United States Europe. Patients with a CHADS2 score 3 or...
Abstract Aims To assess the tolerability of initiating/uptitrating sacubitril/valsartan (LCZ696) from 50 to 200 mg twice daily (target dose) over 3 and 6 weeks in heart failure (HF) patients (ejection fraction ≤35%). Methods results A 5‐day open‐label run‐in (sacubitril/valsartan daily) preceded an 11‐week, double‐blind, randomization period [100 for 2 followed by (‘condensed’ regimen) vs. weeks, 100 (‘conservative’ regimen)]. Patients were stratified pre‐study dose angiotensin‐converting...
Background and Purpose— Adequate diagnosis of atrial fibrillation (AF), including paroxysmal AF, is an important part stroke workup. Prolonged ECG monitoring may improve the detection paroxysmal, previously undiagnosed AF (unknown AF). Therefore, we evaluated systematic 72-hour Holter to detect unknown for workup patients with stroke. Methods— Unselected survivors a or transient ischemic attack (TIA) without known were enrolled in prospective, multicenter cohort study 9 German secondary...
Atrial fibrillation (AF) is a major cause of preventable strokes. Screening asymptomatic individuals for AF may increase anticoagulant use stroke prevention.To evaluate 2 home-based screening interventions.This multicenter randomized clinical trial recruited from primary care practices aged 75 years or older with hypertension and without known AF. From April 5, 2015, to March 26, 2019, 856 participants were enrolled 48 practices.The control group received standard (routine follow-up plus...
Abstract Aims To systematically assess late outcomes of acute pulmonary embolism (PE) and to investigate the clinical implications post-PE impairment (PPEI) fulfilling prospectively defined criteria. Methods results A prospective multicentre observational cohort study was conducted in 17 large-volume centres across Germany. Adult consecutive patients with confirmed symptomatic PE were followed a standardized assessment plan pre-defined visits at 3, 12, 24 months. The co-primary (i) diagnosis...
<h3>Importance</h3> There is limited evidence on the benefits of sacubitril/valsartan vs broader renin angiotensin system inhibitor background therapy surrogate outcome markers, 6-minute walk distance, and quality life in patients with heart failure mildly reduced or preserved left ventricular ejection fraction (LVEF >40%). <h3>Objective</h3> To evaluate effect N-terminal pro–brain natriuretic peptide (NT-proBNP) levels, medication–based individualized comparators chronic LVEF more than...
BACKGROUND: Rivaroxaban and dabigatran were not superior to aspirin in trials of patients with embolic stroke undetermined source (ESUS). It is unknown whether apixaban ESUS known risk factors for cardioembolism. METHODS: We conducted a multicenter, randomized, open-label, blinded-outcome trial (5 mg twice daily) compared (100 once initiated within 28 days after at least one predictive factor atrial fibrillation or patent foramen ovale. Cardiac monitoring was mandatory, treatment switched...
An interatrial shunt may provide an autoregulatory mechanism to decrease left atrial pressure and improve heart failure (HF) symptoms prognosis.
Direct oral anticoagulants (DOACs) reduce the rate of thromboembolism in patients with atrial fibrillation but benefits and risks survivors intracerebral haemorrhage are uncertain. We aimed to determine whether DOACs risk ischaemic stroke without substantially increasing recurrent haemorrhage. PRESTIGE-AF is a multicentre, open-label, randomised, phase 3 trial conducted at 75 hospitals six European countries. Eligible were aged 18 years or older spontaneous haemorrhage, fibrillation, an...
Background and Purpose— Diagnosis of paroxysmal atrial fibrillation is difficult but highly relevant in patients presenting with cerebral ischemia yet free from on admission. Early initiation prolongation continuous Holter monitoring may improve diagnostic yield compared the standard care including a 24-hour recording. Methods— In observational Find-AF trial (ISRCTN 46104198), consecutive symptoms were included. Patients at presentation received 7-day monitoring. Results— Two hundred...